Status:
COMPLETED
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
Lead Sponsor:
Onze Lieve Vrouwe Gasthuis
Conditions:
Kidney Failure, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venove...
Detailed Description
Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. Renal function generally recovers if the acute illness improves. To bridge this period, renal...
Eligibility Criteria
Inclusion
- Intensive care patients scheduled for continuous venovenous hemofiltration
Exclusion
- Severe pre-existent liver failure (cirrhosis Child C), acute liver dysfunction as occurring with septic shock is not a reason for exclusion
- Active bleeding or bleeding necessitating the infusion of two red blood cell units within 24 hours before starting hemofiltration or a fall in hemoglobin of \> 0.5 mmol/l. A fall in hemoglobin/hematocrit as a result of fluid loading is not regarded as bleeding.
- Surgery within 24 h prior to CVVH.
- Patients needing full systemic anticoagulation (unfractionated heparin in a dose of \> 10000 IU/day, or nadroparin \> 3800 IU/day) for other reasons
- Expectation to die within 24 hours
- Chronic dialysis
- Proven or suspected heparin-induced thrombocytopenia
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT00286273
Start Date
March 1 2003
End Date
March 1 2008
Last Update
August 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands, 1090HM